Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir.

Bourry O, Brochard P, Souquiere S, Makuwa M, Calvo J, Dereudre-Bosquet N, Martinon F, Benech H, Kazanji M, Le Grand R.

AIDS. 2009 Feb 20;23(4):447-54. doi: 10.1097/QAD.0b013e328321302d.

PMID:
19240457
2.

Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy.

Benlhassan-Chahour K, Penit C, Dioszeghy V, Vasseur F, Janvier G, Rivière Y, Dereuddre-Bosquet N, Dormont D, Le Grand R, Vaslin B.

J Virol. 2003 Dec;77(23):12479-93.

3.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
4.

Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.

Kuritzkes DR, Bassett RL, Johnson VA, Marschner IC, Eron JJ, Sommadossi JP, Acosta EP, Murphy RL, Fife K, Wood K, Bell D, Martinez A, Pettinelli CB.

AIDS. 2000 Jul 28;14(11):1553-61.

PMID:
10983642
5.

Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.

Havlir DV, Gilbert PB, Bennett K, Collier AC, Hirsch MS, Tebas P, Adams EM, Wheat LJ, Goodwin D, Schnittman S, Holohan MK, Richman DD; ACTG 5025 Study Group.

AIDS. 2001 Jul 27;15(11):1379-88.

PMID:
11504959
6.

Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion.

Bourry O, Mannioui A, Sellier P, Roucairol C, Durand-Gasselin L, Dereuddre-Bosquet N, Benech H, Roques P, Le Grand R.

Retrovirology. 2010 Sep 26;7:78. doi: 10.1186/1742-4690-7-78.

7.

Effect of dosing frequency on ZDV prophylaxis in macaques infected with simian immunodeficiency virus.

Tsai CC, Follis KE, Grant RF, Nolte RE, Bartz CR, Benveniste RE, Sager PR.

J Acquir Immune Defic Syndr. 1993 Oct;6(10):1086-92.

PMID:
8410666
8.

The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.

Winston A, McAllister J, Amin J, Cooper DA, Carr A.

HIV Med. 2005 May;6(3):191-7.

9.

Is AZT/3TC therapy effective against FIV infection or immunopathogenesis?

Arai M, Earl DD, Yamamoto JK.

Vet Immunol Immunopathol. 2002 Mar;85(3-4):189-204.

PMID:
11943320
11.

Variation in virological parameters and antibody responses in macaques after atraumatic vaginal exposure to a pathogenic primary isolate of SIVmac251.

Neildez O, Le Grand R, Chéret A, Caufour P, Vaslin B, Matheux F, Théodoro F, Roques P, Dormont D.

Res Virol. 1998 Jan-Feb;149(1):53-68.

PMID:
9561564
12.

Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.

Luque A, Hulse S, Wang D, Shahzad U, Tanzman E, Antenozzi S, Smith B.

Infect Control Hosp Epidemiol. 2007 Jun;28(6):695-701. Epub 2007 May 8.

PMID:
17520543
13.

Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.

Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, Martin A, Pau CP, Hanson DL, Guenthner P, Smith J, Kersh E, Garcia-Lerma JG, Novembre FJ, Otten R, Folks T, Heneine W.

J Virol. 2009 Oct;83(20):10358-65. doi: 10.1128/JVI.01073-09. Epub 2009 Aug 5.

14.

Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.

Launay O, Gérard L, Morand-Joubert L, Flandre P, Guiramand-Hugon S, Joly V, Peytavin G, Certain A, Lévy C, Rivet S, Jacomet C, Aboulker JP, Yéni P; Agence Nationale de Recherches sur le SIDA (ANRS) 081 Study Group.

Clin Infect Dis. 2002 Nov 1;35(9):1096-105. Epub 2002 Oct 15.

PMID:
12384844
15.

Rapid viral decay in simian immunodeficiency virus-infected macaques receiving quadruple antiretroviral therapy.

Brandin E, Thorstensson R, Bonhoeffer S, Albert J.

J Virol. 2006 Oct;80(19):9861-4.

16.
17.

Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys.

Olivero OA, Fernandez JJ, Antiochos BB, Wagner JL, St Claire ME, Poirier MC.

J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):323-9. Erratum in: J Acquir Immune Defic Syndr 2002 Jul 1;30(3):368.

PMID:
11917235
18.
19.

Repetitive exposures with simian/human immunodeficiency viruses: strategy to study HIV pre-clinical interventions in non-human primates.

Kim CN, Adams DR, Bashirian S, Butera S, Folks TM, Otten RA.

J Med Primatol. 2006 Aug;35(4-5):210-6.

PMID:
16872284
20.

Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study.

Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, Swai A, Lipyoga R, Mhalu F, Biberfeld G; Mitra Plus Study Team.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):406-16. doi: 10.1097/QAI.0b013e3181b323ff.

PMID:
19730269

Supplemental Content

Support Center